Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAtla’s therapeutic development division VivaMab and ADC Therapeutics Sarl have signed a licensing agreement for a new antibody against an undisclosed hematological cancer target.
Subscribe to our email newsletter
Under the terms of the agreement, ADC Therapeutics has licensed a VivaMab antibody, VM101, produced using BioAtla’s Express Humanization, Comprehensive Positional Evolution, Combinatorial Protein Synthesis affinity and functional maturation technology platforms.
VM101 is mutually combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a new ADC, which is already proved to have powerful in vivo efficacy in recognized models for normally intractable hematological cancer indications.
ADC Therapeutics has planned to begin pre-IND development of the ADC immediately, simultaneously with its other advanced ADC programs with development support from VivaMab, which will receive a share of potential milestones and royalties on the drug.
VivaMab president William Boyle said that the BioAtla platform has generated a superior internalizing antibody to the target of interest, allowing to generate and develop an ADC drug candidate for hematologic cancers.
"The combination of a uniquely potent BioAtla antibody with a potent drug conjugate, or warhead, is likely to enhance therapeutic outcomes in its target indication," Boyle added.
The financial terms of the licensing deal were not disclosed.